Further studies demonstrate that constitutive activation of AKT promotes CSLC resistance to treatment with chemotherapy and/or radiation therapy partially by downregulating the expression of p27 [17], a well-known tumor suppressor. The gene discussed is AKT1; the disease is neoplasm.